Sustainable tuberculosis drug development

Clinical Infectious Diseases

Volumn 56, Issue 1, 2013, Pages 106-113

  Wallis, Robert S ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

adaptive licensing; drug development; oxazolidinone; surrogate endpoint; tuberculosis

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AZD 5847; BEDAQUILINE; CLOFAZIMINE; DELAMANID; ETHAMBUTOL; IMATINIB; ISONIAZID; N (2 ADAMANTYL) N' GERANYLETHYLENEDIAMINE; PLACEBO; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN; SUTEZOLID; THIOACETAZONE; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG;

BACTERICIDAL ACTIVITY; DRUG BLOOD LEVEL; DRUG DEVELOPMENT; DRUG EFFICACY; DRUG RESISTANT TUBERCULOSIS; DRUG SAFETY; HEALTH CARE COST; HUMAN; PRIORITY JOURNAL; REVIEW; SPUTUM CULTURE; TUBERCULOSIS;

ANIMALS; ANTITUBERCULAR AGENTS; BIOLOGICAL MARKERS; CLINICAL TRIALS AS TOPIC; DRUG DISCOVERY; HUMANS; MICE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REGRESSION ANALYSIS; SPUTUM; TUBERCULOSIS; TUBERCULOSIS, MULTIDRUG-RESISTANT; WORLD HEALTH;

EID: 84871201297     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cis849     Document Type: Review

References (58)

1. World Health Organization. TB: A global emergency. Geneva: WHO; 1994. Report No.: WF 205 94 TB C.2.
2. World Health Organization. Global tuberculosis control: WHO report 2011. Geneva: WHO; 2011 Report No.: WHO/HTM/TB/2011.16.
3. World Health Organization. Anti-tuberculosis drug resistance in the world: Report no. 1. 1997. Report No.: WHO/TB/97.229.
4. World Health Organization. Towards universal access to diagnosis and treatment of M/XDR-TB: WHO progress report 2011. Geneva: WHO; 2011. Report No.: WHO/HTM/TB/2011.3.
5. Haxaire-Theeuwes M. Phase 2 open-label trial of TMC207 in an MDRTB treatment regimen. Union World Conf Lung Health 2011;42. Abstract Symposium 46. Available at: http://uwclh.conference2web. com/content/all#/?search=haxaire.
6. Wallis RS, Patil S, Cheon SH, et al. Drug tolerance in Mycobacterium tuberculosis. Antimicrob Agents Chemother 1999; 43:2600-6.
7. Gumbo T, Louie A, Liu W, et al. Isoniazid's bactericidal activity ceases because of the emergence of resistance, not depletion of Mycobacterium tuberculosis in the log phase of growth. J Infect Dis 2007; 195:194-201.
8. Wallis RS, Palaci M, Eisenach K. Persistence, not resistance, is the cause of loss of isoniazid effect. J Infect Dis 2007; 195:1870-1.
9. Dorman SE, Johnson JL, Goldberg S, et al. Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis. Am J Respir Crit Care Med 2009; 180:273-80.
10. Nuermberger EL, Yoshimatsu T, Tyagi S, et al. Moxifloxacin-containing regimens of reduced duration produce a stable cure in murine tuberculosis. Am J Respir Crit Care Med 2004; 170:1131-4.
11. Rosenthal IM, Tasneen R, Peloquin CA, et al. Dose-ranging comparison of rifampin and rifapentine in two pathologically distinct murine models of tuberculosis. Antimicrob Agents Chemother 2012; 56: 4331-40.
12. Dorman SE, Goldberg S, Stout JE, et al. Substitution of rifapentine for rifampin during intensive phase treatment of pulmonary tuberculosis: study 29 of the Tuberculosis Trials Consortium. J Infect Dis 2012; 206:1030-40.
13. Wallis RS. Assessment of whole blood bactericidal activity in the evaluation of new anti-tuberculosis drugs. In: Donald PR, van Helden P, eds. Antituberculosis chemotherapy. Basel: Karger, 2011:220-6.
14. Janulionis E, Sofer C, Song HY, Wallis RS. Lack of activity of oral clofazimine against intracellular M. tuberculosis in whole blood culture. Antimicrob Agents Chemother 2004; 48:3133-5.
15. Wallis RS, Wang C, Doherty TM, et al. Biomarkers for tuberculosis disease activity, cure, and relapse. Lancet Infect Dis 2010; 10:68-9.
16. Wallis RS, Jakubiec W, Mitton-Fry M, et al. Rapid evaluation in whole blood culture of regimens for XDR-TB containing PNU-100480 (Sutezolid), TMC207, PA-824, SQ109, and pyrazinamide. PLoS One 2012; 7:e30479.
17. Reddy VM, Dubuisson T, Einck L, et al. SQ109 and PNU-100480 interact to kill Mycobacterium tuberculosis in vitro. J Antimicrob Chemother 2012; 67:1163-66.
18. Reddy VM, Einck L, Andries K, Nacy CA. In vitro interactions between new antitubercular candidates SQ109 and TMC207. Antimicrob Agents Chemother 2011; 54:2840-6.
19. Williams K, Minkowski A, Amoabeng O, et al. Sterilizing activity of novel combination lacking first and second-line drugs in a murine model of tuberculosis. Antimicrob Agents Chemother 2012; 56:3114-20.
20. Tasneen R, Li SY, Peloquin CA, et al. Sterilizing activity of novel TMC207-and PA-824-containing regimens in a murine model of tuberculosis. Antimicrob Agents Chemother 2011; 55: 5485-92.
21. Diacon AH, Dawson R, du BJ, et al. Phase II dose-ranging trial of the early bactericidal activity of PA-824. Antimicrob Agents Chemother 2012; 56:3027-31.
22. Diacon AH, Dawson R, Hanekom M, et al. Early bactericidal activity and pharmacokinetics of PA-824 in smear-positive tuberculosis patients. Antimicrob Agents Chemother 2010; 54:3402-7.
23. Franzblau S, Cho S, Kim Y, et al. Anti-tuberculosis in vitro activity profile of the nitroimidazole TBA-354. ICAAC 2012; 52. Abstract F-834.
24. Idh J, Mekonnen M, Abate E, et al. Resistance to first-line anti-TB drugs is associated with reduced nitric oxide susceptibility in Mycobacterium tuberculosis. PLoS One 2012; 7:e39891.
25. Wallis RS, Phillips M, Johnson JL, et al. Inhibition of INH-induced expression of M. tuberculosis antigen 85 in sputum: a potential surrogate marker in TB chemotherapy trials. Antimicrob Agents Chemother 2001; 45:1302-4.
26. Dietze R, Teixeira L, Rocha LM, et al. Safety and bactericidal activity of rifalazil in patients with pulmonary tuberculosis. Antimicrob Agents Chemother 2001; 45:1972-6.
27. Brindle R, Odhiambo J, Mitchison DA. Serial counts of Mycobacterium tuberculosis in sputum as surrogate markers of the sterilising activity of rifampicin and pyrazinamide in treating pulmonary tuberculosis. BMC Pulm Med 2001; 1:2.
28. Rustomjee R, Diacon AH, Allen J, et al. Early bactericidal activity and pharmacokinetics of the diarylquinoline TMC 207 in pulmonary tuberculosis. Antimicrob Agents Chemother 2008; 52:2831-5.
29. Johnson JL, Hadad DJ, Dietze R, et al. Shortening treatment in adults with noncavitary tuberculosis and 2-month culture conversion. Am J Respir Crit Care Med 2009; 180:558-63.
30. Chowdhury A, Santra A, Kundu S, et al. Induction of oxidative stress in antitubercular drug-induced hepatotoxicity. Indian J Gastroenterol 2001; 20:97-100.
31. Palanisamy GS, Kirk NM, Ackart DF, Shanley CA, Orme IM, Basaraba RJ. Evidence for oxidative stress and defective antioxidant response in guinea pigs with tuberculosis. PLoS One 2011; 6:e26254.
32. Baniasadi S, Eftekhari P, Tabarsi P, et al. Protective effect of N-acetylcysteine on antituberculosis drug-induced hepatotoxicity. Eur J Gastroenterol Hepatol 2010; 22:1235-8.
33. Gandelman K, Zhu T, Fahmi OA, et al. Unexpected effect of rifampin on the pharmacokinetics of linezolid: in silico and in vitro approaches to explain its mechanism. J Clin Pharmacol 2011; 51: 229-36.
34. Kang YA, Choi YJ, Cho YJ, et al. Cost of treatment for multidrugresistant tuberculosis in South Korea. Respirology 2006; 11:793-8.
35. Padayatchi N, Mac Kenzie WR, Hirsch-Moverman Y, et al. Lessons from a randomized clinical trial for multi-drug resistant tuberculosis. Int J Tuberc Lung Dis. In press.
36. Veziris N, Ibrahim M, Lounis N, Andries K, Jarlier V. Sterilizing activity of second-line regimens containing TMC207 in a murine model of tuberculosis. PLoS One 2011; 6:e17556.
37. Eichler HG, Oye K, Baird LG, et al. Adaptive licensing: taking the next step in the evolution of drug approval. Clin Pharmacol Ther 2012; 91:426-37.
38. Wells WA, Ge CF, Patel N, Oh T, Gardiner E, Kimerling ME. Size and usage patterns of private TB drug markets in the high burden countries. PLoS One 2011; 6:e18964.
39. Eichler HG, Abadie E, Breckenridge A, et al. Bridging the efficacy-effectiveness gap: a regulator's perspective on addressing variability of drug response. Nat Rev Drug Discov 2011; 10:495-506.
40. D'Agostino RB Jr. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 1998; 17:2265-81.
41. Gadabu OJ, Munthali CV, Zachariah R, et al. Is transcript of data on antiretroviral treatment from electronic to paper-based registers reliable in Malawi? Public Health Action 2011; 1:10-2.
42. Haagsma AC, Abdillahi-Ibrahim R, Wagner MJ, et al. Selectivity of TMC207 towards mycobacterial ATP synthase compared with that towards the eukaryotic homologue. Antimicrob Agents Chemother 2009; 53:1290-2.
43. Diacon AH, Pym A, Grobusch M, et al. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med 2009; 360: 2397-405.
44. Manjunatha U, Boshoff HI, Barry CE. The mechanism of action of PA-824: novel insights from transcriptional profiling. Commun Integr Biol 2009; 2:215-8.
45. Singh R, Manjunatha U, Boshoff HI, et al. PA-824 kills nonreplicating Mycobacterium tuberculosis by intracellular NO release. Science 2008; 322:1392-5.
46. Gler MT, Skripconoka V, Sanchez-Garavito E, et al. Delamanid for multidrug-resistant pulmonary tuberculosis. N Engl J Med 2012; 366:2151-60.
47. Diacon AH, Dawson R, von Groote-Bidlingmaier F, et al. 14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial. Lancet 2012; 380:986-93.
48. Wallis RS, Jakubiec W, Kumar V, et al. Pharmacokinetics and whole blood bactericidal activity against Mycobacterium tuberculosis of single ascending doses of PNU-100480 in healthy volunteers. J Infect Dis 2010; 202:745-51.
49. Wallis RS, Jakubiec W, Kumar V, et al. Biomarker assisted dose selection for safety and efficacy in early development of PNU-100480 for tuberculosis. Antimicrob Agents Chemother 2011; 55:567-74.
50. Wallis RS, Friedrich SO, Diacon AH, et al. PK and bactericidal activity in blood and sputum of sutezolid (PNU-100480) and its major metabolite (PNU-101603) in patients with pulmonary TB. ICAAC 2012; 52. Abstract A-1264.
51. Balasubramanian V, Gaonkar S, Solapure S, et al. AZD5847, an oxazolidinone for the treatment of tuberculosis: pre-clinical studies. ICAAC 2011; 51. Abstract 1364.
52. Tahlan K, Wilson R, Kastrinsky DB, et al. SQ109 targets MmpL3, a membrane transporter of trehalose monomycolate involved in mycolic acid donation to the cell wall core of Mycobacterium tuberculosis. Antimicrob Agents Chemother 2012; 56:1797-1809.
53. Nikonenko BV, Protopopova M, Samala R, Einck L, Nacy CA. Drug therapy of experimental tuberculosis (TB): improved outcome by combining SQ109, a new diamine antibiotic, with existing TB drugs. Antimicrob Agents Chemother 2007; 51:1563-5.
54. Jia L, Noker PE, Coward L, Gorman GS, Protopopova M, Tomaszewski JE. Interspecies pharmacokinetics and in vitro metabolism of SQ109. Br J Pharmacol 2006; 147:476-85.
55. Anonymous. Clofazimine. Tuberculosis (Edinb) 2008; 88:96-9.
56. Van DA, Salim MA, Das AP, Bastian I, Portaels F. Results of a standardised regimen for multidrug-resistant tuberculosis in Bangladesh. Int J Tuberc Lung Dis 2004; 8:560-7.
57. Huang H, Liu K, Zhang D, et al. SAR of riminophenazine class and discovery of new anti-tuberculosis agents active against multidrugresistant tuberculosis. ICAAC 2011; 51. Abstract 1358.
58. Napier RJ, Rafi W, Cheruvu M, et al. Imatinib-sensitive tyrosine kinases regulate mycobacterial pathogenesis and represent therapeutic targets against tuberculosis. Cell Host Microbe 2011; 10:475-85.